---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269534"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:06:55.733225+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M

## Summary
- Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.
- Revenue $3.7M, down ~$0.1M YoY; cash $40.5M expected to fund ops into Q2 2027.
- Entered collaboration with William Demant Invest for ReSonance (ANP1); up to $12M development funding.
- Positive 36-month OpRegen (RG6501) data in dry AMD presented at CTS 2025.
- First chronic SCI participant dosed in OPC1 DOSED study; no safety events at 60 days.

## SEC filing metadata
- accession: 0001193125-25-269534
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/0001193125-25-269534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312525269534/lctx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269534
- JSON: https://secwatch.observer/filing/0001193125-25-269534.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.